AN2 Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for AN2 Therapeutics, Inc. (ANTX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ANTX insiders buying or selling?
In the last 12 months, AN2 Therapeutics, Inc. insiders reported 1 open-market purchase ($11.6K) and 13 sales ($398.3K) — net selling of $386.7K. Since March 2022, Trabud has recorded 68 Form 4 filings for ANTX: 21 buys ($53.8M) and 47 sells ($19.0M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $11.6K by Margaret M Fitzpatrick (Director) on Sep 2, 2026. SEC ↗
- The most recent open-market purchase was reported on Sep 2, 2026 (46 days ago).
Key Statistics (March 2022 – Sep 11, 2026)
Total Form 4 filings
68
SEC EDGAR
Insider filers
14
Insider buys (21)
$53.8M
Insider sells (47)
$19.0M
Insider sentiment
Net buyingNet insider flow of $34.7M in net buying since March 2022, and $386.7K in net selling over the last 12 months. 1 insider buy in the last 90 days.
Recent ANTX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Robin Shane Readnour | Director | Sale | 1.1K | $6.02 | $6.7K | SEC ↗ |
| Sep 8, 2026 | Robin Shane Readnour | Director | Sale | 16.1K | $6.04 | $97.3K | SEC ↗ |
| Sep 4, 2026 | Sarah Joanne Williams | Principal Accounting Officer | Sale | 272 | $5.53 | $1.5K | SEC ↗ |
| Sep 2, 2026 | Margaret M Fitzpatrick | Director | Purchase | 2.1K | $5.53 | $11.6K | SEC ↗ |
| Aug 19, 2026 | Robin Shane Readnour | Director | Sale | 35.4K | $6.01 | $212.7K | SEC ↗ |
| Jul 10, 2026 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 5.9K | $4.17 | $24.8K | SEC ↗ |
| Jun 2, 2026 | Sarah Joanne Williams | Principal Accounting Officer | Sale | 265 | $4.43 | $1.2K | SEC ↗ |
| Mar 5, 2026 | Sarah Joanne Williams | Principal Accounting Officer | Sale | 327 | $1.06 | $346.62 | SEC ↗ |
| Jan 8, 2026 | Lucy Day | Chief Financial Officer | Sale | 8.8K | $1.01 | $8.9K | SEC ↗ |
| Jan 8, 2026 | Stephen David Prior | Chief Strategy Officer | Sale | 6.5K | $1.01 | $6.5K | SEC ↗ |
| Jan 8, 2026 | Sanjay Chanda | Chief Development Officer | Sale | 9.3K | $1.01 | $9.3K | SEC ↗ |
| Jan 8, 2026 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 24.9K | $1.00 | $25.0K | SEC ↗ |
| Nov 6, 2025 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 2.8K | $1.14 | $3.2K | SEC ↗ |
| Nov 6, 2025 | Stephen David Prior | Chief Strategy Officer | Sale | 765 | $1.14 | $872.1 | SEC ↗ |
| Jun 16, 2025 | Braden Michael Leonard | 10% Owner | Sale | 200.0K | $1.09 | $218.0K | SEC ↗ |
| Jun 3, 2025 | Easom Eric | Chief Executive Officer | Purchase | 10.0K | $1.07 | $10.7K | SEC ↗ |
| May 30, 2025 | Braden Michael Leonard | 10% Owner | Sale | 2.5M | $1.13 | $2.9M | SEC ↗ |
| May 29, 2025 | Margaret M Fitzpatrick | Director | Purchase | 8.6K | $1.18 | $10.1K | SEC ↗ |
| Jan 8, 2025 | Lucy Day | Chief Financial Officer | Sale | 3.0K | $1.34 | $4.0K | SEC ↗ |
| Jan 8, 2025 | Sanjay Chanda | Chief Development Officer | Sale | 3.0K | $1.34 | $4.0K | SEC ↗ |
| Jan 8, 2025 | Stephen David Prior | Chief Strategy Officer | Sale | 2.0K | $1.34 | $2.7K | SEC ↗ |
| Jan 8, 2025 | Joshua M Eizen | Chief Operating Officer and Chief Legal Officer | Sale | 9.7K | $1.34 | $13.0K | SEC ↗ |
| Dec 11, 2024 | Robin Shane Readnour | Director | Purchase | 60.0K | $1.45 | $86.7K | SEC ↗ |
| Nov 28, 2024 | Robin Shane Readnour | Director | Purchase | 75.0K | $1.41 | $105.7K | SEC ↗ |
| Nov 27, 2024 | Joseph S Zakrzewski | Director | Purchase | 2.0K | $1.40 | $2.8K | SEC ↗ |
Showing the 25 most recent of 68 Form 4 filings for AN2 Therapeutics, Inc..
Most active ANTX insiders
- Easom Eric11 filings
- Adjuvant Global Health Technology Fund L.P.9 filings
- Robin Shane Readnour9 filings
- Kabeer Aziz8 filings
- Peter Kolchinsky7 filings
Ask anything about ANTX insider activity
Use Trabud's AI agent to query AN2 Therapeutics, Inc.'s Form 4 history in plain English — "Show me ANTX CEO purchases this year" or compare it against any other ticker.
Open the AI agentANTX insider trading FAQ
Are AN2 Therapeutics, Inc. insiders buying or selling?
In the last 12 months, AN2 Therapeutics, Inc. insiders reported 1 open-market purchase ($11.6K) and 13 sales ($398.3K) — net selling of $386.7K. Since March 2022, Trabud has recorded 68 Form 4 filings for ANTX: 21 buys ($53.8M) and 47 sells ($19.0M). Over the full record that is net buying of $34.7M.
How many insiders trade ANTX stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for AN2 Therapeutics, Inc.. The most recent filing was accepted on Sep 11, 2026.
Where does Trabud get ANTX insider trading data?
All ANTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.